[Modern therapy of hematologic malignancies]
- PMID: 11787232
[Modern therapy of hematologic malignancies]
Abstract
Remarkable progress has been done during the last three decades in the therapy of hematological malignancies. It is now possible to cure significant number of patients by chemotherapy, radiotherapy, and stem cell transplantation. However, there is still a large group of patients and situations where our approaches are failing. It is evident that in some circumstance chemotherapy and radiotherapy get close to their limits. A short insight into the group of novel therapeutic methods is given in this review. Such promising methods of treatment include the new chemotherapeutic drugs, new molecules that specifically act on the level molecular mechanisms (STI 571, ATRA, arsenic trioxide, etc.), immunotherapy (monoclonal antibodies, vaccination strategy, exploration of dendritic cells etc.), gene therapy and innovations in stem cell transplantation (graft versus leukemia/lymphoma effect). The future treatment will include combination of standard or intensified chemo/radiotherapy and the new methods, which allow better control of the disease.
Similar articles
-
Alloreactivity as therapeutic principle in the treatment of hematologic malignancies. Studies of clinical and immunologic aspects of allogeneic hematopoietic cell transplantation with nonmyeloablative conditioning.Dan Med Bull. 2007 May;54(2):112-39. Dan Med Bull. 2007. PMID: 17521527 Review.
-
Manipulation of the stem cell as a target for hematologic malignancies.Semin Oncol. 2000 Oct;27(5):512-23. Semin Oncol. 2000. PMID: 11049019 Review.
-
Hematopoietic stem cell transplant as a platform for tumor immunotherapy.Curr Opin Mol Ther. 2004 Feb;6(1):48-53. Curr Opin Mol Ther. 2004. PMID: 15011781 Review.
-
Hematopoietic stem cell transplantation in hematologic malignancy.Panminerva Med. 2004 Mar;46(1):61-74. Panminerva Med. 2004. PMID: 15238882 Review.
-
Allogeneic blood stem cell transplantation after a reduced-intensity, preparative regimen: a pilot study in patients with refractory malignancies.Cancer. 2002 May 1;94(9):2409-15. doi: 10.1002/cncr.10491. Cancer. 2002. PMID: 12015766